# Cross Labeling Oncology Drugs in Combination Regimens - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/cross-labeling-oncology-drugs-in-combination-regimens/d50f604f-4d0f-4aaa-a83a-b8a75b4a71ee

> FDA guidance document: Cross Labeling Oncology Drugs in Combination Regimens. Issue date: November 02, 2022. Get complete insights and analysis.

---

## Details

- Title: Cross Labeling Oncology Drugs in Combination Regimens
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2022-11-02
- Last Changed: 2022-11-08
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2020-D-2107">FDA-2020-D-2107</a>

## Related Documents

- [Bladder Cancer: Developing Drugs and Biologics for Adjuvant Treatment:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/bladder-cancer-developing-drugs-and-biologics-for-adjuvant-treatment-guidance-for-industry/b3fd959c-72c5-4e86-a4a9-5fa31d0ce7b7)
- [Inclusion of Older Adults in Cancer Clinical Trials:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/inclusion-of-older-adults-in-cancer-clinical-trials-guidance-for-industry/58e758a2-a626-41ba-8346-44066b8cd50f)
- [Male Breast Cancer: Developing Drugs for Treatment:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/male-breast-cancer-developing-drugs-for-treatment-guidance-for-industry/76829c69-4547-4b3d-bde5-9bf7ef4e1490)